What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

Ingo Ahrens; Gregory Y. H. Lip; Karlheinz Peter

doi:10.1160/TH10-12-0808

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(04): 574-578
DOI: 10.1160/TH10-12-0808

Clinical Focus

Schattauer GmbH

What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

Ingo Ahrens

¹Innere Medizin III, Kardiologie und Angiologie, Universitätsklinik Freiburg, Germany

,

Gregory Y. H. Lip

²University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Karlheinz Peter

³Atherothrombosis & Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne,Victoria, Australia

› Author Affiliations

Abstract

Full Text

References

References
1 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
2 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3 Ezekowitz MD, Wallentin L, Connolly SJ. et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010; 122: 2246-2253.
4 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
5 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
6 Diener HC, Connolly SJ, Ezekowitz MD. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163.
7 Eikelboom JW, O’Donnell M, Yusuf S. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-353.
8 AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding. Available at www.theheart.org Accessed on August 31, 2010.
9 Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds. Available at www.theheart.org Accessed on November 15, 2010.
10 Roskell NS, Lip GY, Noack H. et al. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
11 Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost 2010; 104: 657-663.
12 Ruiz-Nodar JM, Marin F, Manzano-Fernandez S. et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation undergoing percutaneous coronary revascularisation. Chest. 2010 preprint online.
13 Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?. Am J Med 2010; 123: 785-789.
14 Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
15 Jiang J, Hu Y, Zhang J. et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thromb Haemost 2010; 103: 234-241.
16 Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.
17 Ezekowitz MD, Connolly S, Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-10 810.e1–2.
18 Koti MJ, Parekh A, Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation – An analysis of patients undergoing cardioversion. J Am Coll Cardiol 2010; 55: 1078-1124 (Abstract).
19 Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005; 46: 1986-1995.
20 FDA approves dabigatran for stroke prevention, embolism, in AF patients. Available at www.theheart.org Accessed on October 20, 2010.
21 Eisert WG, Hauel N, Stangier J. et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-1889.
22 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
23 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
24 Furie KL, Kasner SE, Adams RJ. et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Health-care Professionals From the American Heart Association/American Stroke Association. Stroke. 2010 prepublished online.